SPRED2 Loss Drives Liver Cancer Stemness via p53/miR-506-3p/KLF4 Axis

Researchers have identified a novel tumor-suppressive circuit involving SPRED2, p53, and miR-506-3p that controls cancer stem cell traits in hepatocellular carcinoma, offering potential new therapeutic targets to reduce recurrence and treatment resistance.

Chicago Metrowire Staff
••Healthcare
SPRED2 Loss Drives Liver Cancer Stemness via p53/miR-506-3p/KLF4 Axis

Researchers have uncovered a previously unrecognized molecular pathway that governs stem-like behavior in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The study, published in Cancer Biology & Medicine, details how the protein SPRED2 collaborates with the tumor suppressor p53 to activate a microRNA that suppresses cancer stem cells (CSCs). The findings could lead to new strategies for combating HCC recurrence, metastasis, and chemotherapy resistance, which remain major clinical challenges.

Liver cancer is the fifth most commonly diagnosed cancer and the second leading cause of cancer death worldwide. HCC accounts for 70–85% of primary liver cancers, and its five-year recurrence rate can reach 70–80%. CSCs, a small but aggressive subpopulation, are thought to drive relapse and treatment failure. SPRED2, known to inhibit Ras/Raf/ERK-MAPK signaling, is downregulated in advanced cancers, and its loss has been linked to increased levels of pluripotency factors such as Nanog, c-Myc, and KLF4. However, the exact mechanism by which SPRED2 controls HCC stemness was unclear until now.

Led by researchers at Okayama University in Japan, the study combined cell line experiments, mouse models, and human HCC samples to map the pathway. The team found that SPRED2 binds to p53, enters the nucleus, and activates transcription of miR-506-3p. This microRNA then directly targets KLF4 messenger RNA, reducing KLF4 protein levels and thereby diminishing CSC traits such as sphere formation, colony growth, invasion, and aldehyde dehydrogenase (ALDH) activity. The study defines a SPRED2/p53/miR-506-3p/KLF4 axis, with KLF4 acting as a key pluripotency factor that promotes stemness. Knocking down KLF4 reduced CSC properties and tumor growth in mice, and also lowered Nanog and c-Myc, placing KLF4 upstream of these factors.

Clinical samples validated the findings: in 40 paired human HCC samples, KLF4 and miR-506-3p were negatively correlated, while SPRED2 and miR-506-3p were positively correlated. Mechanistically, SPRED2 formed a nuclear complex with p53, and p53 supported SPRED2 nuclear localization and bound the miR-506 promoter. SPRED2 increased miR-506-3p in a p53-dependent, dose-dependent manner. Additionally, inhibition of ERK and STAT3 signaling also raised miR-506-3p, linking three pathways to KLF4 suppression. These results show that SPRED2 coordinates ERK, STAT3, and p53 signaling to reduce HCC stemness.

The authors noted that the findings reveal a previously unrecognized tumor-suppressive circuit linking SPRED2 to p53 and microRNA regulation. They emphasized that SPRED2 does not act only by blocking ERK or STAT3 signaling; it also helps p53 drive miR-506-3p, which then keeps KLF4 in check. This axis may explain why loss of SPRED2 promotes CSC-like behavior and could offer a fresh target for therapies aimed at reducing HCC stemness. The pathway may be especially important because it connects three signaling routes to a single stemness regulator.

Targeting the SPRED2/p53/miR-506-3p/KLF4 axis may provide new therapeutic strategies for HCC. Restoring miR-506-3p or SPRED2 activity could lower KLF4 and inhibit CSC traits, potentially reducing relapse, metastasis, and chemoresistance. Because SPRED2-driven miR-506-3p induction required functional p53, the approach may be most relevant for tumors with intact p53 signaling; HCC cells with mutant or absent p53 may need additional strategies. Future studies should test miR-506-3p mimics, SPRED2-stabilizing agents, or combination therapies in preclinical models and define which patients are most likely to benefit. Such work could help translate this newly defined axis into precision approaches for HCC. The full study is available at DOI: 10.20892/j.issn.2095-3941.2025.0247.

Blockchain Registration

QR Code for Blockchain Registration